Saba Capital Management’s Tevogen Bio Holdings TVGN Stock Holding History

Saba Capital Management’s Portfolio TVGN Stock Details TVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-64,899	Closed	-$33.5M	–	810
2022 Q4	$33.5M	Buy	64,899 +1,767	+3%	+$904K	0.45%	28
2022 Q3	$32M	Hold	63,132	–	–	0.36%	30
2022 Q2	$31.6M	Hold	63,132	–	–	0.37%	24
2022 Q1	$31.5M	Buy	+63,132	New	+$31.4M	0.45%	14

Other funds holding TVGN

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Saba Capital Management's TVGN Position: Q1 2023 in Review

Saba Capital Management sold out of Tevogen Bio Holdings (TVGN) in Q1 2023, closing a stake of 64,899 shares — an estimated $33.5M sold.

Saba Capital Management first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $33.5M in Q4 2022. 4 funds tracked by Wall St. Rank hold TVGN as of Q1 2023.

Saba Capital Management reported no remaining Tevogen Bio Holdings position as of Q1 2023 after selling out during the quarter.
Saba Capital Management sold 64,899 Tevogen Bio Holdings shares in Q1 2023, an estimated $33.5M.
Saba Capital Management first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 4 quarters.
Saba Capital Management's Tevogen Bio Holdings position peaked at $33.5M in Q4 2022.
4 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2023.

Based on Saba Capital Management's 13F filing for Q1 2023, filed 15 May 2023.